

References

L-96

1. Rosenson R, Underberg J. Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. *Cardiovascular Drugs Therapy*. 2013; 27:46-479.
2. Garber A, Abrahamson M, Barzilay J, et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. *Endocrine Practice*. May/June 2013; 19(2):1-48.
3. Stone N, Robinson J, Lichtenstein A, et al. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. *Journal of the American College of Cardiology*. November 2013.
4. Cole T, Contois J, Csako G, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: Assessment by the American Association for Clinical Chemistry (AACC) lipoprotein and vascular diseases division working group on best practices. *Clinical Chemistry*. 2013; 59(5):752-770.
5. Rizzo J, Mallow P, Waters H, et al. Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: A cost-effectiveness analysis. *Journal of Clinical Lipidology*. 2013; 7:642-652.
6. Sniderman A, Kwiterovich P. Update on the detection and treatment of atherogenic low-density lipoproteins. *Current Opinion Endocrinology Diabetes Obesity*. 2013; 20:140-147.
7. Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. June 2013; 128:e240-e327.
8. Chan J, Iqbal N, Butterfield J, et al. Altered forms of brain natriuretic peptide in patients with dyspnea: Diagnostic sensitivity and specificity for heart failure. *Journal of the American College of Cardiology*. April 2014; 63(12).
9. Nishimura K, Nishimura T, Onishi K, et al. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. *International Journal of Chronic Obstructive Pulmonary Disease*. 2014; 9:155-162.
10. Goff D, Jones D, Bennett G, et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the assessment of cardiovascular risk. *Circulation*. November 2013.
11. Albers J, Slee A, O'Brien K, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). *Journal of the American College of Cardiology*. Oct 22 2013; 62(17):1575-1579.
12. Nestel P, Barnes E, Tonkin A, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. *Arteriosclerosis Thrombosis and Vascular Biology*. Dec 2013; 33(12):2902-2908.
13. Khera A, Everett B, Caulfield M, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*. Feb 11 2014; 129(6):635-642.

14. Ripatti S, Salomaa V. How could use of genetic markers prevent coronary heart disease events? *Personalized Medicine*. 2013; 10(8):769-771.
15. Jacobson T, Ito M, Maki K, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary. *Journal of Clinical Lipidology*. 2014; 8:473-488.
16. Master S, Rader D. Beyond LDL Cholesterol in Assessing Cardiovascular Risk: apo B or LDL-P? *Clinical Chemistry*. 2013; 59(5):723-725.
17. Toth P, Grabner M, Punekar R, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*. 2014; 235(2):585-591.
18. Cole T, Contois J, Csako G, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy–derived LDL particle number with outcomes in 25 clinical studies: Assessment by the American Association for Clinical Chemistry (AACC) lipoprotein and vascular diseases division working group on best practices. *Clinical Chemistry*. February 2013; 59:5.
19. Mora S, Glynn R, Ridker P. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. *Circulation*. September 2013; 128(11):1189-1197.
20. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, nonHDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. *Journal of the American Heart Association*. 2014; 3(2):e000759.
21. Rankin N, Preiss D, Welsh P, et al. The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. *Atherosclerosis*. 2014; 237: 287e300.
22. Morris P, McLain K, Malave H, et al. Relationship between plasma apolipoprotein B concentrations and LDL particle number. *Research Reports in Clinical Cardiology*. 2014;5 237–242.
23. Manson J, Bassuk S. Biomarkers of cardiovascular disease risk in women. *Metabolism*. March 2015; 64(3):S33-S39.
24. Willeit P, Thompson S, Agewall S, et al. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. *European Journal of Preventive Cardiology*. January 2016; 23(2):194-205.
25. Moe G, Exekowitz J, O’Meara E, et al. The 2014 Canadian Cardiovascular Society Heart Failure Management guidelines focus update: Anemia, biomarkers, and recent therapeutic trial implications. *Canadian Journal of Cardiology*. January 2015; 31(1):3-16.
26. Francis G. A Test in Context Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. *J Am Coll Cardiol*. 2016;67(3): 330-337.
27. Sofat R. Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Metaanalysis of Results from Three Studies. *PLOS Medicine*. 2016: 1-19.
28. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. 2016.